Aptamer-mediated hollow MnO₂ for targeting the delivery of sorafenib

Abstract

Sorafenib (SRF) presents undesirable effects in clinical treatment, due to the lack of targeting, poor water solubility, and obvious side effects. In this study, we constructed a novel nanodrug carrier system for accurate and efficient delivery of SRF, improving its therapeutic effects and achieving tumor-specific imaging. The hollow mesoporous MnO₂ (H-MnO₂) nanoparticles equipped with target substance aptamers (APT) on the surface were used to load SRF for the first time. The resulting H-MnO₂-SRF-APT could specifically bound to glypican-3 (GPC3) receptors on the surface of hepatocellular carcinoma (HCC), rapidly undergoing subsequent degradation under decreased pH conditions in the tumor microenvironment (TME) and releasing the loaded SRF. In this process, Mn²⁺ ions were used for T₁-weighted magnetic resonance imaging simultaneously. The in vitro cell experiments indicated that H-MnO₂-SRF-APT showed much more effects on the inhibition in the proliferation of Huh7 and HepG2 HCC cells than that of the non-targeted H-MnO₂-SRF and free SRF. Besides, the in vivo results further confirmed that H-MnO₂-SRF-APT could effectively inhibit the growth of xenograft tumors Huh7 in the naked mouse with good biosafety. In conclusion, H-MnO₂-SRF-APT could significantly enhance the therapeutic effect of SRF and is expected to be a new way of diagnosis and treatment of HCC.

Keywords:

• Hollow mesoporous MnO₂
• drug delivery system
• HCC
• MR imaging

Acknowledgments

The authors would like to thank Prof. Li Wang for guiding my experiments and Prof. Liguo Hao for his kind help with flow cytometry analysis. We also thank Jinren Liu for supporting magnetic resonance imaging.

Disclosure statement

No potential conflict of interest was reported by the authors.

Data availability statement

The data and materials in the current study are available from the first author upon reasonable request.

Additional information

Funding

This work is supported by the Qiqihar Medical University Postgraduate Innovation Fund Project (No. QYYCX2022-04).